KRAS and non-small cell lung carcinoma: These results suggested that patients with KRAS wt NSCLC and PD-L1 expression ≥ 50%, treated with anti-PD-1 in monotherapy had worse survival than patients with mt KRAS NSCLC, while there was no difference in survival with chemo-antiPD1, suggesting that chemo-antiPD1 might be preferable in patients with KRAS wt and high PD-L1 expression (33).